ClinicalTrials.gg
CompletedNCT07001553GLaDUpdated Mar 2, 2026

Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

An observational study in Obesity and Type 2 Diabetes Mellitus (T2DM), sponsored by Australian Catholic University. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Australian Catholic University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
37
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Enrollment
15th of 19
37 · median 626
Started
2025
with 24 others
Observational
19 of 188
5 open now
Registered
133rd of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 15th largest by enrollment of the 19 observational ones that give a count, is one of 25 that started in 2025, is one of 19 observational ones, and was the 133rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health.

Read the detailed description

Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will be recruited to participate over the initial 3 months of their treatment. Assessments will occur remotely (online) at baseline, 2 weeks, 1 month and 3 months. Optional body composition assessments will be provided at baseline and 3 months for those based in Melbourne, Australia.

03

Conditions studied

  • Obesity
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • dietary behaviours
  • psychosocial health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals living in Australia who are intending to commence a GLP-1 prescription

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18+ years old
  • Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
  • The primary reason for commencing the medication will be for diabetes or weight management
  • Willing to participate in dietary recall and questionnaires

Exclusion criteria

Exclusion Criteria:

  • Aged under 18 years,
  • used a GLP-1 agonist medication in the previous 6 months,
  • unwilling or unable to provide dietary recalls
  • non-English speaking.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
37 participants (actual)
Patient registry
No

Groups and cohorts

  • Weight management

    Prescribed GLP-1 agonist therapy primarily for weight management

  • Type 2 diabetes

    Prescribed GLP-1 agonist therapy primarily for glycemic management

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment

    The rate of recruitment and the retention rate of participants completing the dietary assessment measures.

    Time frame: 4 months

Secondary outcomes

  1. Energy intake

    Assessed using Intake24 records for at least 2 days per timepoint

    Time frame: baseline, 2 weeks, 1 month, 3 months

  2. Medication symptomology

    Incidence of self-reported side effects

    Time frame: baseline, 1 month, 3 months

  3. Medication use

    Dosage

    Time frame: baseline, 1 month, 3 months

Other outcomes

  1. Patient perspectives

    Qualitative interview after end of the observation period

    Time frame: 3 months

  2. Macronutrient intake

    Proportion of carbohdyrate, fat, protein, alcohol and fibre intake assessed through dietary records

    Time frame: baseline, 2 weeks, 1 month, 3 months

  3. Diet quality

    Assessed using Healthy Eating Index for Australian adults (HEIFA) from diet records (Intake24)

    Time frame: baseline, 2 weeks, 1 month, 3 months

  4. Meal timing

    Daily eating window and meal timing

    Time frame: baseline, 2 weeks, 1 month, 3 months

  5. Medication use

    Timing of medication use

    Time frame: baseline, 1 month, 3 months

  6. Retrospective subjective appetite

    Assessed using adaptive visual analogue scales with appetite questions as per Flint et al 2020 and used by Ravussin et al 2025, scored between 0 to 100, with a higher score meaning higher appetite ratings

    Time frame: baseline, 1 month, 3 months

  7. Treatment self-regulation

    Assessed using Treatment Self-regulation Questionnaire, 15 questions which are scored between 1 (not at all) and 7 (completely true) in response to questions

    Time frame: baseline, 1 month, 3 months

  8. Food cravings

    Assessed using Control of Eating Questionnaire (COEQ), a 21 questionnaire survey with a 0-100 scale where higher responses indicate higher severity of food cravings.

    Time frame: baseline, 1 month, 3 months

  9. Internalisation of weight bias

    Assessed using Weight Bias Internalisation Scale-Modified (WBIS-M), which includes 11 questions that are answered on a 1 (strongly disagree) to 7 (strongly agree) scale, noting that 2 questions are reverse scored.

    Time frame: baseline, 1 month, 3 months

  10. Intuitive eating

    Assessed using Intuitive Eating Scale 3 (IES-3), including 12 questions with options from 1 (strongly disagree) to 5 (strongly agree) where the higher total score indicates higher intuitive eating (Tykla et al, Appetite, 2024)

    Time frame: baseline, 1 month, 3 months

  11. Health-related quality of life

    Assessed using Short Form-36 (SF-36) questionnaire, where 36 questions are asked regarding the previous 4 weeks. Questions are given a score between 0 to 100 depending, and the overall score is the average of all questions.

    Time frame: baseline, 1 month, 3 months

  12. Well being

    Quality of life assessed using WHO-5 well being index, including 5 questions scored from 0 (none of the time) to 5 (all of the time), where a higher total score indicates better quality of life.

    Time frame: baseline, 1 month, 3 months

  13. Binge eating

    Assessed using Binge eating scale, which includes 16 questions. The total score ranges from 0 to 46, with higher scores correlating with more frequent and severe binge eating behaviours.

    Time frame: baseline, 1 month, 3 months

  14. Disordered eating behaviours

    Assessed using Eating Disorders Examination Questionnaire (EDEQ) 6.0, using 28 questions which are scored on 4 sub-scales and a global score is generated as an average of the 4 sub-scales. A higher score indicates greater disordered eating behaviours.

    Time frame: baseline, 1 month, 3 months

  15. Physical activity

    Assessed using International Physical Activity Questionnaire (long), which is 27 questions which asks duration (minutes) and frequency (days) of physical activity measured in domains of: 1) Job-related; 2) Transportation; 3) Housework, house maintenance, caring for family; 4) Recreation, sport, and leisure-time; and 5) Time spent sitting. An overall score is calculated using responses to all questions, where a higher score equates to greater physical activity.

    Time frame: baseline, 1 month, 3 months

  16. Dietary changes

    Assessed using Australian Eating Survey Food Frequency Questionnaire (FFQ), which has 120-item with 15 supplementary questions. The FFQ is designed to collect information about dietary intake over the participants previous 3 months.

    Time frame: baseline, 3 months

  17. Micronutrient intake

    Proportion of micronutrient intake (i.e. including but not limited to sodium, calcium, iron, zinc, vitamins, etc) assessed through dietary records

    Time frame: baseline, 2 weeks, 1 month, 3 months

07

Study locations

1 site
  • Australian Catholic University
    Fitzroy, Victoria 3065, Australia
08

References and documents

Individual participant data

Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publically available, as it contains information that could compromise research participant consent.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 36 months from date of publication

Access criteria: Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jan 2026, 7 months.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 7 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 3, 2025
StartActual
May 28, 2025
Primary completionActual
Jan 7, 2026
CompletionActual
Jan 7, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001553
Lead sponsor
Australian Catholic University
Collaborators
St Vincent's Hospital Melbourne, The University of Queensland
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
May 28, 2025
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update
Mar 2, 2026

Study contacts

Evelyn B Parr, PhD
principal investigator · Australian Catholic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion